Fang Li1, Baihui Zhu2, Guihui Xie1, Yan Wang1, Jianmei Geng1. 1. Department of Pediatrics, Taizhou Jiangyan Hospital of Traditional Chinese Medicine, Taizhou, China. 2. Department of Pediatrics, Maternity and Child Health Care of Zaozhuang, Zaozhuang, China - shenhai19992000@163.com.
Abstract
BACKGROUND: There has been a paucity of data about the therapeutic efficacy of bronchoalveolar lavage (BAL) for pediatric refractory mycoplasma pneumonia pneumonia (RMPP) complicated with atelectasis. This study aimed to evaluate the clinical effectiveness and safety of BAL in pediatric RMPP inpatients complicated with atelectasis. METHODS: Totally 225 children diagnosed as having RMPP with radiological proven irreversible atelectasis completed this study. According to whether they received BAL treatment, they were divided into BAL-intervention group (N.=125) and the control group (N.=100). Clinical, laboratory and radiological effects were compared between these two groups. Bronchoscopic imaging features were also comprehensively investigated. RESULTS: Compared with control group, the febrile days after enrollment was significantly shorter in BAL-intervention group (3.0±1.6 d) compared with that in control group (4.1±1.7 d) (P<0.01). The duration of coughing was 3.1±1.7 d in BAL-intervention group and 4.6±1.8 days in the control group (P<0.01). The duration of abnormal lung auscultation was 3.8±1.8 d in intervention group and 5.8±1.6 d in the control group (P<0.01). The length of hospital stays was 5.8±1.6 days and 7.8±1.9 days (P<0.01), respectively. We also found that WBC count (P<0.01) and CRP value (P<0.01) recovered more quickly in BAL-intervention group compared with that in the control group. Seven days after admission, 85.6% of patients in BAL-intervention group showed atelectasis resolution versus 39.0% in control group (P<0.01), and for pleural effusion disappearance 78.4% versus 43.0% (P<0.01). CONCLUSIONS: Our data suggested that BAL intervention combined with regular drug usage and prednisolone is a better treatment for RMPP children complicated with atelectasis than conventional drug therapy alone.
BACKGROUND: There has been a paucity of data about the therapeutic efficacy of bronchoalveolar lavage (BAL) for pediatric refractory mycoplasma pneumonia pneumonia (RMPP) complicated with atelectasis. This study aimed to evaluate the clinical effectiveness and safety of BAL in pediatric RMPP inpatients complicated with atelectasis. METHODS: Totally 225 children diagnosed as having RMPP with radiological proven irreversible atelectasis completed this study. According to whether they received BAL treatment, they were divided into BAL-intervention group (N.=125) and the control group (N.=100). Clinical, laboratory and radiological effects were compared between these two groups. Bronchoscopic imaging features were also comprehensively investigated. RESULTS: Compared with control group, the febrile days after enrollment was significantly shorter in BAL-intervention group (3.0±1.6 d) compared with that in control group (4.1±1.7 d) (P<0.01). The duration of coughing was 3.1±1.7 d in BAL-intervention group and 4.6±1.8 days in the control group (P<0.01). The duration of abnormal lung auscultation was 3.8±1.8 d in intervention group and 5.8±1.6 d in the control group (P<0.01). The length of hospital stays was 5.8±1.6 days and 7.8±1.9 days (P<0.01), respectively. We also found that WBC count (P<0.01) and CRP value (P<0.01) recovered more quickly in BAL-intervention group compared with that in the control group. Seven days after admission, 85.6% of patients in BAL-intervention group showed atelectasis resolution versus 39.0% in control group (P<0.01), and for pleural effusion disappearance 78.4% versus 43.0% (P<0.01). CONCLUSIONS: Our data suggested that BAL intervention combined with regular drug usage and prednisolone is a better treatment for RMPP children complicated with atelectasis than conventional drug therapy alone.